美国马里兰州罗克维尔市和中国苏州2025年3月26日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）今日宣布，公司共有五项临床前研究进展入选2025年美国癌症研究协会（AACR）年会。此次会议将于 2025 年 4 月 25 日至 30 日在美国芝加哥举行。

and oblimersen could become the first FDA-approved BCL-2 inhibitor. BCL-2 antagonists will probably begin their commercial lives as products that disable the anti-apoptotic machinery and restore ...

Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 12.22%, which has investors questioning if this is right time ...

including a BTK inhibitor and a BCL-2 inhibitor in December 2023. It was approved for the MCL indication in the United States in January 2023. Jaypirca is one of Lilly’s several new drugs that ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka ...